Stockscreener 앱 받기
2.10
4.11%
-0.09
시간 외 거래:
2.05
-0.05
-2.38%
전일 마감가:
$2.19
열려 있는:
$2.2
하루 거래량:
1.20M
Relative Volume:
0.64
시가총액:
$72.54M
수익:
$300.00K
순이익/손실:
$-24.74M
주가수익비율:
-2.0875
EPS:
-1.006
순현금흐름:
$-19.19M
1주 성능:
-15.66%
1개월 성능:
-14.29%
6개월 성능:
+144.41%
1년 성능:
-52.16%
1일 변동 폭
$1.9801
$2.21
1주일 범위
$1.9801
$2.745
52주 변동 폭
$0.5562
$4.99
iBio Inc Stock (IBIO) Company Profile
명칭
iBio Inc
전화
302-355-0650
주소
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
2.10 | 75.65M | 300.00K | -24.74M | -19.19M | -1.006 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Oppenheimer | Outperform |
| 2025-10-17 | 개시 | Leerink Partners | Outperform |
| 2024-05-28 | 개시 | Chardan Capital Markets | Buy |
| 2021-11-29 | 개시 | JMP Securities | Mkt Outperform |
| 2021-01-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-06-26 | 개시 | Alliance Global Partners | Buy |
모두보기
iBio Inc 주식(IBIO)의 최신 뉴스
IBIO: Analyst Keay Nakae Reaffirms 'Buy' Rating with $5.00 Price Target | IBIO Stock News - GuruFocus
Aug Opening: How do insiders feel about iBio IncQuarterly Trade Report & Low Drawdown Trading Strategies - baoquankhu1.vn
Jones Trading reiterates iBio stock rating on pulmonary hypertension expansion - Investing.com
VIX Spike: Is IBIO in a long term uptrend2026 PreEarnings & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
iBio (NASDAQ:IBIO) Given Buy Rating at Chardan Capital - MarketBeat
iBio (IBIO) to Discuss Pipeline Expansion in Upcoming Conference Call - GuruFocus
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - The Manila Times
Stop Loss: How sensitive is iBio Inc to inflationWeekly Gains Report & Real-Time Chart Pattern Alerts - baoquankhu1.vn
iBio to Provide an Update on Cardiopulmonary Program - GlobeNewswire
iBio reports fat reduction in primate obesity study By Investing.com - Investing.com Nigeria
Ibio SEC Filings - Stock Titan
iBio, Inc. (NASDAQ:IBIO) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Highs Report: Is iBio Inc a turnaround storyRate Cut & Reliable Price Action Trade Plans - baoquankhu1.vn
IBIO: Advancing novel antibody therapies for obesity and cardiometabolic disease with strong clinical momentum - TradingView
Jones Trading reiterates iBio stock rating on obesity drug data - Investing.com
iBio Reports Promising Preclinical Results for IBIO-610 Activin E Antibody in Fat-Selective Weight Loss for Obesity and Cardiometabolic Diseases 1 - Minichart
IBIO: Innovative antibody pipeline aims for fat-specific weight loss and muscle preservation in obesity - TradingView
iBio reports fat reduction in primate obesity study - Investing.com India
iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential - TipRanks
iBio (IBIO) Reports Promising Preclinical Results for Obesity Tr - GuruFocus
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss - Bitget
Primate obesity study backs iBio fat-loss antibody, twice-yearly dosing potential - Stock Titan
[EFFECT] iBio, Inc. SEC Filing - Stock Titan
Leerink Partners Maintains IBio Inc(IBIO.US) With Buy Rating, Raises Target Price to $5 - 富途牛牛
Cash per share of iBio, Inc. – MUN:0JV0 - TradingView
IBIO Stock Price, Quote & Chart | IBIO INC (NASDAQ:IBIO) - ChartMill
iBio (NASDAQ:IBIO) Upgraded by JonesTrading to Strong-Buy Rating - MarketBeat
Jones Trading Initiates Coverage of iBio (IBIO) with Buy Recommendation - Nasdaq
JonesTrading Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $7 - 富途牛牛
iBio (IBIO) Receives New 'Buy' Rating from Jones Trading | IBIO Stock News - GuruFocus
iBio (NYSE:IBIO) Now Covered by Analysts at JonesTrading - MarketBeat
Jones Trading initiates iBio stock with buy rating on obesity platform - Investing.com India
Jones Trading initiates iBio stock with buy rating on obesity platform By Investing.com - Investing.com South Africa
Revenue per share of iBio, Inc. – MUN:0JV0 - TradingView
Ibio Ends At-The-Market Equity Offering Program - The Globe and Mail
iBio (NASDAQ:IBIO) Raised to Hold at Wall Street Zen - MarketBeat
IBio enters open market sale agreement with Jefferies - marketscreener.com
IBio Files $200 Million Mixed Shelf Offering - marketscreener.com
iBio Launches Up to $100 Million ATM Program With Jefferies to Bolster Liquidity - TradingView
iBio (NYSE: IBIO) launches $100M at-the-market stock offering with Jefferies - Stock Titan
IBio Inc files for mixed shelf of up to $200 million - marketscreener.com
iBio Inc Files For Mixed Shelf Of Upto $200 Million - TradingView
Ken Johnson - Crain's Chicago Business
IBIO: Pipeline advances in obesity and cardiovascular drugs with strong financial backing and near-term data - TradingView
IBIO: Advancing next-gen obesity therapies with strong financials and key data readouts ahead - TradingView
Growth Report: Will iBio Inc benefit from green energy policiesMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
LifeSci Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
Aug Selloffs: Is Beazer Homes USA Inc forming a breakout patternTrade Entry Report & Long-Term Growth Portfolio Plans - baoquankhu1.vn
iBio (NYSEMKT:IBIO) Stock Price Up 2.9%Should You Buy? - MarketBeat
How do insiders feel about iBio Inc.Rate Cut & Step-by-Step Swing Trade Plans - mfd.ru
iBio to Participate in Upcoming Investor Conferences - The Manila Times
iBio Inc (IBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):